P. Sevelda - Concepedia

Author

P. Sevelda

Also Known As

Alexander Reinthaller, Arik Galid, Catharina Wenzel, Christian Schauer, P Sevelda, P. SEVELDA, P. Sevelda, PAUL SEVELDA, Paul Sevelda, Peter Oppelt

342

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

University of Vienna Medical University of Vienna Klinik Hietzing Hanusch Hospital Comprehensive Cancer Center Vienna

About

P. Sevelda is an author at University of Vienna specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	46	3.9K
2	Health Sciences	8	8	974
3	Engineering	2	2	63
4	Biomedical Engineering	2	2	62
5	Public Health	1	1	50

P. Sevelda

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors Martin Filipits, Margaretha Rudas, R. Jakesz, Clinical Cancer Research	2011	703
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma Ignace Vergote, Jos De Brabanter, Anthony Fyles, The Lancet MedicineSurgical PathologyEpithelial Ovarian CarcinomaPathologyGynecology	2001	626
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial Michael Gnant, Georg Pfeiler, Peter Dubsky, The Lancet Breast OncologyOncologyClinical TrialsAdjuvant DenosumabPlacebo-controlled Trial	2015	543
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, Annals of Oncology Zoledronic AcidBreast OncologyEndocrine OncologyMedicinePharmacology	2014	300
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial Michael Gnant, Georg Pfeiler, Günther Steger, The Lancet Oncology Breast OncologyMedicineClinical TrialsAdjuvant DenosumabDisease-free Survival Results	2019	231
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. J Fischer-Colbrie, Armin Witt, Harald Heinzl, PubMed Breast OncologyProgesterone ReceptorSteroid ReceptorsGynecologyPathology	1997	154
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer Michael Gnant, Florian Fitzal, Gabriel Rinnerthaler, New England Journal of Medicine	2021	151
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Marco Colleoni, Weixiu Luo, Per Karlsson, The Lancet Oncology Breast OncologyMedicineCancer ManagementGynecologyBreast Cancer	2017	120
Prognostic factors for survival in Stage I epithelial ovarian carcinoma P. Sevelda, Norbert Vávra, M. Schemper, Cancer Prognostic FactorsSurgical OncologyCox ModelTumoral PathologyGynecological Surgery	1990	112

Page 1